Paper42701351
The Evolution of Medications for Obesity Management.
Gill J and 1 other. JGH Open, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The Evolution of Medications for Obesity Management. Papers, record 42701351. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42701351
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References85
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40544433 | Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40544433 | PubMed |
| 2 | 40960239 | Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40960239 | PubMed |
| 3 | 18095746 | Orlistat-associated adverse effects and drug interactions: a critical review. | Drug Saf | 2008 | https://conductscience.org/library/papers/18095746 | PubMed |
| 4 | 37796527 | Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. | JAMA | 2023 | https://conductscience.org/library/papers/37796527 | PubMed |
| 5 | 41018564 | Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions. | Obes Pillars | 2025 | https://conductscience.org/library/papers/41018564 | PubMed |
| 6 | 42418774 | Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. | N Engl J Med | 2026 | https://conductscience.org/library/papers/42418774 | PubMed |
| 7 | 38829659 | Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant? | JAMA | 2024 | https://conductscience.org/library/papers/38829659 | PubMed |
| 8 | 22822160 | Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice. | Endocrinology | 2012 | https://conductscience.org/library/papers/22822160 | PubMed |
| 9 | 33137293 | Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. | Lancet Diabetes Endocrinol | 2020 | https://conductscience.org/library/papers/33137293 | PubMed |
| 10 | 41138739 | Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. | Lancet | 2025 | https://conductscience.org/library/papers/41138739 | PubMed |
| 11 | 42252333 | Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. | Nat Med | 2026 | https://conductscience.org/library/papers/42252333 | PubMed |
| 12 | 20673995 | Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2010 | https://conductscience.org/library/papers/20673995 | PubMed |
| 13 | 40450457 | Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. | Am J Clin Nutr | 2025 | https://conductscience.org/library/papers/40450457 | PubMed |
| 14 | 39476339 | Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39476339 | PubMed |
| 15 | 22915024 | Anti-obesity drugs: past, present and future. | Dis Model Mech | 2012 | https://conductscience.org/library/papers/22915024 | PubMed |
| 16 | 37934220 | Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. | JAMA | 2023 | https://conductscience.org/library/papers/37934220 | PubMed |
| 17 | 21481449 | Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. | Lancet | 2011 | https://conductscience.org/library/papers/21481449 | PubMed |
| 18 | 31750601 | Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. | Diabetes Obes Metab | 2020 | https://conductscience.org/library/papers/31750601 | PubMed |
| 19 | 40804463 | Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. | Int J Obes (Lond) | 2025 | https://conductscience.org/library/papers/40804463 | PubMed |
| 20 | 37881914 | Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration. | Ann Pharmacother | 2024 | https://conductscience.org/library/papers/37881914 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42701351
GET https://conductscience.org/api/papers/v1/42701351/references?page=2